-65%

est. 2Y upside i

HealthcareSeries A

Power Life Science believes that every patient deserves the chance to participate in a life-changing clinical trial. Is backed by some of the best healthcare investors and operators with a range of experience across clinical research and biopharmaceuticals. We are a small team - each of us with our own personal story and motivation to make a difference in the lives of patients.

Rank

#1001

Sector

HealthTech

Est. Liquidity

~5Y

Data Quality

Data: Medium

Power presents a moderate upside opportunity for a job seeker, driven by its innovative AI-powered approach to a critical and growing market ($4.6B SAM for patient recruitment).

Last updated: March 10, 2026

Bull (25%)+300%

Power successfully scales its AI-powered marketplace, capturing significant market share from legacy systems like ClinicalTrials.gov and outcompeting smaller rivals. By 2028, it expands its service offerings, achieving an estimated $280M valuation, driven by strong network effects and high patient/researcher engagement.

Base (40%)+100%

Power establishes itself as a niche leader in patient-centric clinical trial recruitment, growing steadily but facing persistent competition from well-funded players like myTomorrows and Dyania Health. It achieves a modest exit or next funding round at a $140M valuation by 2028.

Bear (35%)-80%

Power struggles to differentiate against larger CROs and well-funded health tech competitors, or faces significant regulatory hurdles. Growth stalls, leading to a down round or acquisition at a distressed valuation of $14M, which, given the $19M in liquidation preferences, would wipe out most common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $19M in liquidation preferences, representing 27.14% of the estimated $70M post-money Series A valuation.

Dilution Risk

high

As a Series A company, Power will likely require multiple additional funding rounds (Series B, C, etc.), which will lead to significant future dilution for common shareholders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Power's equity at this early stage.

Questions to Ask at the Interview

Strategic questions based on Power's data — designed to show you've done your homework.

  • 1

    “Given the increasing competition from well-funded players like myTomorrows and Dyania Health, how does Power plan to sustain and strengthen its competitive moat, particularly regarding its AI capabilities and network effects?”

  • 2

    “With over 600,000 patients using Power to discover trials and study team participation growing 20% monthly, what are the key metrics the company is tracking to demonstrate revenue growth and market penetration, and what is the strategy for converting this engagement into a scalable revenue model?”

  • 3

    “Considering the Series A funding and the typical timeline for venture-backed companies, what is the company's anticipated path to a liquidity event (e.g., IPO or acquisition) over the next 3-5 years, and how does the current equity structure impact employee compensation in various exit scenarios?”

Community

Valuation Sentiment

Our model estimates -65% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.